Janux Therapeutics, Inc. (NASDAQ:JANX) Stock Holdings Lowered by Rafferty Asset Management LLC

Rafferty Asset Management LLC lessened its position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 20.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 52,168 shares of the company's stock after selling 13,522 shares during the period. Rafferty Asset Management LLC owned about 0.10% of Janux Therapeutics worth $2,793,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the company. Russell Investments Group Ltd. increased its position in Janux Therapeutics by 77.7% during the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock worth $54,000 after purchasing an additional 442 shares during the last quarter. Rhumbline Advisers increased its position in Janux Therapeutics by 1.6% during the fourth quarter. Rhumbline Advisers now owns 38,153 shares of the company's stock worth $2,043,000 after purchasing an additional 599 shares during the last quarter. Kennedy Capital Management LLC increased its position in Janux Therapeutics by 7.9% during the fourth quarter. Kennedy Capital Management LLC now owns 12,713 shares of the company's stock worth $681,000 after purchasing an additional 928 shares during the last quarter. MetLife Investment Management LLC increased its position in Janux Therapeutics by 5.8% during the fourth quarter. MetLife Investment Management LLC now owns 17,298 shares of the company's stock worth $926,000 after purchasing an additional 949 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in Janux Therapeutics by 10.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company's stock worth $596,000 after purchasing an additional 1,095 shares during the last quarter. Institutional investors and hedge funds own 75.39% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on JANX shares. Scotiabank dropped their price objective on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a research report on Friday, February 28th. HC Wainwright reissued a "buy" rating and issued a $70.00 price objective on shares of Janux Therapeutics in a research report on Monday, March 3rd. Finally, Wedbush reaffirmed an "outperform" rating and set a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. One analyst has rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Janux Therapeutics presently has a consensus rating of "Buy" and an average price target of $95.25.

Janux Therapeutics Stock Performance

Shares of Janux Therapeutics stock traded up $0.01 during trading hours on Friday, reaching $25.22. The company's stock had a trading volume of 1,181,341 shares, compared to its average volume of 874,124. The company's 50 day simple moving average is $28.03 and its 200 day simple moving average is $39.49. Janux Therapeutics, Inc. has a one year low of $22.48 and a one year high of $71.71. The stock has a market cap of $1.49 billion, a P/E ratio of -21.56 and a beta of 3.24.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. On average, sell-side analysts predict that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Insider Activity at Janux Therapeutics

In related news, insider Andrew Hollman Meyer sold 3,333 shares of Janux Therapeutics stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $32.03, for a total value of $106,755.99. Following the sale, the insider now directly owns 82,139 shares in the company, valued at $2,630,912.17. This trade represents a 3.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ra Capital Management, L.P. acquired 110,206 shares of the business's stock in a transaction that occurred on Friday, March 7th. The stock was purchased at an average price of $31.02 per share, for a total transaction of $3,418,590.12. Following the completion of the transaction, the director now owns 10,141,287 shares in the company, valued at $314,582,722.74. The trade was a 1.10% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 10,001 shares of company stock worth $313,964 in the last ninety days. 8.10% of the stock is owned by insiders.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.